WASHINGTON – The embattled drug company whose price hikes of an anti-allergy product sparked calls for a government investigation and a congressional hearing has announced plans to lower the cost of its EpiPen product to consumers.
The company said Thursday that it will increase the value of a savings coupon offered to purchase its epinephrine auto injector to $300 from $100 and double the eligibility for subsidies that eliminate out-of-pocket costs to uninsured or underinsured patients.
Sen. Amy Klobuchar of Minnesota, who has called for a Federal Trade Commission investigation and a Senate Judiciary Committee hearing to explore Mylan’s 400 percent price increase for EpiPens since 2008, welcomed the company’s move.
But Klobuchar, a Democrat, said the country “cannot rely on public outcry as the only solution for high prescription drug prices.”
Mylan CEO Heather Bresch, the daughter of Sen. Joe Manchin, D-W.Va., called the move an attempt to make sure that “everyone who needs an EpiPen Auto Injector gets one.” But Bresch called pricing “only one part of the problem.” She pointed to “a significant burden on patients from continued, rising insurance premiums and (patients) being forced increasingly to pay the full list price for medicines at the pharmacy counter.”
